ASCO 2026 Day 1 Highlights
Friday 29th May
ASCO 2026 Day 1 reinforced the rapid pace of innovation in oncology and the shift toward more personalized, data-driven care, with standout phase 3 results for sunvozertinib and sacituzumab tirumotecan signalling further progress in targeted and combination strategies in lung cancer. Read our key highlights below from Day 1 at ASCO:
Transforming EGFR Exon 20 NSCLC Treatment with Sunvozertinib
Results of WU-KONG28 (LBA8500): A phase 3 randomized trial of sunvozertinib versus platinum-based chemotherapy in frontline EGFR exon 20 insertion NSCLC.
Sunvozertinib is set to redefine treatment for EGFR exon 20 insertion NSCLC, a historically hard-to-treat molecular subgroup. The phase 3 WU-KONG28 study demonstrated that this targeted therapy significantly improved outcomes compared to standard chemotherapy.
- Patients receiving sunvozertinib achieved a median PFS of 10.3 months vs 7.5 months with chemotherapy
- The trial demonstrated a 35% reduction in the risk of progression or death (HR 0.65)
- Objective response rate (ORR) was 58.9% vs 31.1%, highlighting superior anti-tumor activity
- Duration of response was also improved compared to chemotherapy
Sunvozertinib represents one of the first oral targeted therapies to demonstrate superiority over chemotherapy in a phase 3 frontline setting for this patient subgroup, marking a significant step forward in precision oncology.
Advancing First-Line NSCLC Treatment with Sacituzumab Tirumotecan
Results of OptiTROP-Lung05 (Abstract 8506): A phase 3 randomized trial of sacituzumab tirumotecan in combination with pembrolizumab versus pembrolizumab alone in PD-L1–positive advanced NSCLC.
Sacituzumab tirumotecan, combined with pembrolizumab, showed significant improvement in clinical outcomes versus pembrolizumab alone in PD-L1–positive advanced NSCLC. The phase 3 OptiTROP-Lung05 trial demonstrated that this antibody–drug conjugate (ADC)–based combination significantly improves clinical outcomes compared to immunotherapy alone.
- The combination reduced the risk of disease progression or death by 65% (HR 0.35)
- Median PFS was not reached vs 5.7 months with pembrolizumab monotherapy
- Objective response rate (ORR) was 70.2% vs 42%, indicating a higher depth of response
- PFS benefit was observed across PD-L1 subgroups, including both high and low expressors
This study adds to emerging Phase 3 evidence supporting the combination of a TROP2-directed ADC with PD-1 inhibition in treatment-naïve NSCLC without EGFR or ALK alterations, highlighting the growing role of ADC-based combinations in the frontline setting.
Complex Scenarios in Metastatic Breast Cancer
A standout panel session highlighted the rapidly evolving treatment landscape in hormone receptor-positive, HER2-negative metastatic breast cancer, where care is increasingly shifting from a linear approach to more personalized, biomarker-driven strategies. CDK4/6 inhibitors plus endocrine therapy remain foundational in the first line, while next-generation antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan and sacituzumab govitecan are redefining treatment across and increasingly earlier in the continuum. Beyond efficacy, the discussion emphasized the growing complexity around sequencing, resistance, and toxicity management, alongside the need to anchor decisions in patient-defined quality of life through shared decision-making.
As innovation accelerates, a consistent theme emerges: the importance of translating scientific advances into real-world impact by ensuring patients are accurately identified, tested, and connected to the most appropriate therapies bringing precision oncology closer to routine practice.
Meet Diaceutics at ASCO 2026
Meet Diaceutics at ASCO 2026 or Contact Us to discuss how we help you unlock the full potential of your diagnostic-driven therapies. Through working at the intersection of data, science, and commercial strategy, we focus on solving the real-world challenges that limit therapy uptake, helping you find missed patients, improve diagnostic pathways, and act at the moments that matter most.
